Tel Aviv - Delayed Quote ILA

Bio-View Ltd (BIOV.TA)

Compare
30.20
+1.40
+(4.86%)
At close: January 16 at 10:15:01 AM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILA.
NameTitlePayExercisedYear Born
Mr. Daniel Klain President & CEO 2.88M -- 1979
Mr. Elad Kafir Vice President of Marketing 759k -- 1975
Mr. Yuval Harari M.Sc. Deputy Chief Executive Officer 858k -- 1961
Mr. David Kutas President & CEO of Bioview (USA) Inc. 929k -- 1956
Atiya Pine Chief Financial Officer -- -- 1981
Ms. Inbal Shmula Hillel Chief Operating Officer 631k -- 1976
Dr. Chassidy Johnson Chief Scientific Officer -- -- --

Bio-View Ltd

3 Pekeris Street
Rehovot, 7670203
Israel
972 73 227 1025 https://www.bioview.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
33

Description

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an automated imaging system that supports multiple applications; Encore, an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation that streamlines review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was incorporated in 1998 and is headquartered in Rehovot, Israel.

Corporate Governance

Bio-View Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

March 22, 2017 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers